Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Healthy, Renal Dysfunction
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Aging
Interventions: Placebo, Nutritional Supplement, In-home exercise, Testosterone; Drug · Dietary Supplement · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 65 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: Atherosclerosis
Interventions: SB659032; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Stroke, Depression, Anxiety, Coping Skills, Couples
Interventions: ReStoreD; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Human Papillomavirus, Prevention
Interventions: Computer-based tailoring system; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: erlotinib hydrochloride, docetaxel, radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis B
Interventions: Simvastatin, Tenofovir, Entecavir; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Congenital Heart Disease
Interventions: passive range of motion exercise therapy; Other
Lead sponsor: Carelon Research; Other
Eligibility: Up to 35 Days
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Influenza, Human
Interventions: Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug, Poly I:Poly C12U 1250 ug, Placebo, FluMist; Drug
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Organ Transplantation
Interventions: Belatacept, Sirolimus, Alemtuzumab; Drug
Lead sponsor: Allan D Kirk, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Mental Disorders
Interventions: DECIDE-PA, DECIDE-PC; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • Worcester, Massachusetts

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 356
States / cities: Scottsdale, Arizona • Modesto, California • Monterey, California + 231 more

Conditions: Major Depressive Disorder
Interventions: Psychotherapy; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sarcoma, Soft Tissue Sarcoma, Breast Cancer
Interventions: LUM015; Drug
Lead sponsor: David Kirsch; Other
Eligibility: 18 Years to 74 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vascular Anomalies, Vascular Anomaly, TIE2/PIK3CA Pathway Driven Vascular Anomalies
Interventions: alpelisib (BYL719); Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 30 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance Abuse
Interventions: Project ALERT, Getting to Outcomes; Behavioral
Lead sponsor: RAND; Other
Eligibility: 11 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atherosclerosis
Interventions: LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: VTE Prophylaxis
Interventions: Betrixaban; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Healthy Volunteers
Interventions: TAK-881, SC Investigational Needle Sets; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions: Embospheres Microspheres; Device
Lead sponsor: Keith Pereira, MD:; Other
Eligibility: 22 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Cancer
Interventions: cisplatin, fluorouracil, radiation therapy; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

A Study to Assess the Effect of SB 659032 on Platelet Function

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

Promoting Resilience in Stroke Survivor-carepartner Dyads (ReStoreD)

Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Simvastatin for the Treatment of Chronic Hepatitis B

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Safety Study of FluMist With and Without Ampligen

Belatacept Post Depletional Repopulation to Facilitate Tolerance

Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Patient Characteristics and Cognitive vs. Behavioral Therapies for Depression

Cathepsin Activatable Fluorescent Probe

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Testing ALERT With GTO in Middle Schools

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

Study Evaluating Betrixaban in Pediatric Participants

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer